Overview

Thalassaemia, particularly in paediatric patients, presents a series of management challenges that require early diagnosis, appropriate treatment strategies, and ongoing care. Blood transfusions and iron chelation therapy remain cornerstones of treatment, while emerging therapies like gene therapy hold promise for the future. The involvement of a multidisciplinary team is critical to provide holistic care, addressing both the medical and emotional needs of patients and their families.¹

Strategies for paediatric healthcare of thalassaemias

Thalassaemia is a set of congenital blood disorders known for haemoglobin production defects, which cause various haematological and non-haematological consequences. It impacts tens of thousands globally (estimated), especially in areas like the Mediterranean, Southeast Asia, Middle East and Africa regions. There are unique challenges to care among paediatric patients with thalassaemia, necessitating a multifaceted strategy that includes early diagnosis, timely intervention, and long-term management to mitigate disease burden.^1,2 

Let us delve into the challenges thalassaemia poses in children and the management strategies essential for optimal health and wellbeing.

What is thalassaemia?

Thalassaemia is a genetic disorder occurring due to gene mutations in haemoglobin production, leading to a dysfunctional protein type in red blood cells carrying oxygen. There are two primary forms of thalassaemia:

• Alpha-thalassaemia is caused by mutations of the alpha-globin gene. There are four alpha-globin genes in the body, and the severity of alpha-thalassaemia depends on how many of those genes are affected¹
• Beta-thalassaemia: This more common type is caused by mutations in the beta-globin gene. It ranges in severity from thalassaemia minor (a carrier state) to thalassaemia major (which would necessitate frequent blood transfusions)¹

Thalassaemia is a genetic blood disorder affecting children. The possible complications are anaemia, growth problems, bone deformities, and organ damage (iron-induced) secondary to multiple blood transfusions conducted regularly. Early detection and proper treatment are essential for enhancing life quality and prolonging survival.^1,2

Epidemiology of thalassaemia

Thalassaemia is common in regions where malaria used to be endemic, including the Mediterranean, Middle East, and Southeast Asia. Thalassaemia is a genetic disorder that affects 5% of the world population, according to World Health Organisation estimates, with over 300,000 babies born with thalassaemia major or severe thalassaemia intermedia each year.¹

Areas with a high incidence of consanguinity (marriage between close relatives) have a higher incidence of thalassaemia due to an increased risk of genetic disorders inherited by both parents.¹ Genetic counselling and prenatal screening play a crucial role in preventing the births of children with severe forms of the disease. By raising awareness and providing information about the risks, these measures can help parents make informed decisions about family planning.

Complications in managing paediatric thalassaemia

Paediatric thalassaemia is a complex condition that presents multiple challenges in management, including early diagnosis, aggressive medical management, and the psychological and social ramifications of the disease upon the family.

Here are a few of those challenges:

Genetics, early detection, and diagnosis

Early diagnosis of thalassaemia is crucial as it allows for timely initiation of treatment, preventing the development of severe complications. Blood tests to detect abnormal types of haemoglobin can confirm a diagnosis of thalassaemia. Newborn screening programs, which can identify the disease early and reduce the chances of severe complications, have been included in many thalassaemia-affected countries. However, genetic testing and newborn screening are still limited in many low-resource settings, leading to delayed diagnoses and inadequate treatment. As a result, children may be diagnosed only when already manifesting pallor, fatigue, and jaundice – when the disease is already advanced.¹

Blood transfusion-related iron overload

Blood transfusions are one of the backbone therapies for paediatric thalassaemia. These transfusions are critical to avert the life-threatening anaemia that can affect growth, development, and general health. However, repeated transfusions cause dangerously high levels of iron to build up in the body because the body lacks a natural way to excrete excess iron.^1,2

This condition, referred to as iron overload, can harm important organs like the heart, liver, and endocrine glands and come with complications such as heart failure, liver cirrhosis, diabetes, and growth problems. Iron overload management is a significant hurdle in the management of thalassaemia.^1,2

Bone deformities and growth problems 

In thalassaemias, chronic anaemia and iron overload lead to bone deformities and growth problems. The body compensates for the low red blood cell count by expanding the bone marrow, leading to skeletal abnormalities, especially affecting the face and skull. Severe cases result in brittle and fracture-prone bones.¹

Thalassaemia can also lead to delayed growth and delayed puberty in children, affecting overall developmental progress. These physical difficulties can affect a child's self-esteem and quality of life.¹

Psychosocial challenges

Thalassaemia is a chronic disorder that often causes psychological and emotional issues in children who are affected. The stress of frequent hospital visits, the anxiety of blood transfusions, and the need for long-term care can lead to feelings of isolation and foster mental health issues such as anxiety, depression, and adjustment disorders. It's important to address these aspects of care to ensure the overall well-being of the child.^1,2

The family, specifically the parents of a child with thalassaemia, carries a significant burden. They are not only responsible for managing the child's health condition, but also bear the emotional and financial burden of the disease. The constant worry about their child's health, the stress of managing the treatment, and the financial strain of frequent medical expenses can take a toll on the parents' well-being. It's important for healthcare professionals to recognise and support the family's needs in addition to the child's. They play a crucial role in the clinical management of thalassaemia in children. Their expertise and dedication are essential in providing medical therapy, close monitoring, and psychosocial care.
The key strategies include:

Blood transfusions

Blood transfusions are the mainstay of treatment for children with thalassaemia major. They aim to keep haemoglobin levels sufficient to avoid anaemia. Children with thalassaemia major may need transfusions every month. Regular blood transfusion maintains normal growth and development, which has long-term sequelae in the form of iron overload, thereby contributing to the need for additional therapy to mitigate this complication.^1,2,3

Iron chelation therapy

Iron chelation therapy is necessary to combat iron overload in patients regularly receiving blood transfusions. Chelation therapy includes medications that attach to excess iron and help the body get rid of it. The oral chelators are deferasirox and deferiprone, and the intravenous chelation is deferoxamine.^1,2,4

Iron chelation therapy must be individually optimised for every patient, including periodic checkpoints for iron load and organ function. When chelation therapy is not provided in adequate amounts, it can result in severe complications, whereas excessive doses can elicit adverse side effects.^1,2,4

Cell or stem bone marrow transplantation

Children with severe thalassaemia may be treated with a bone marrow or stem cell transplant, which may be curative. This therapy replaces the patient's defective bone marrow with healthy marrow from a compatible donor, usually a sibling. However, the process is not without risks, among them graft-versus-host disease, infections, and complications related to conditioning (pre-transplant chemotherapy or radiation). Bone marrow transplantation is usually considered for young patients in good overall health, as younger patients have better outcomes.⁵

Gene therapy

Recent developments in gene therapy have emerged as a potential cure for thalassaemia. This route includes altering a patient's stem cells to create operational haemoglobin, i.e., gene therapy. It is still in experimental stages, but clinical trials have demonstrated promising results, and gene therapy could eventually be a routine treatment option for global paediatric thalassaemia.⁶

Multidisciplinary care

A multidisciplinary care approach involving haematologists, cardiologists, endocrinologists, psychologists, and other healthcare providers is necessary to optimally manage paediatric thalassaemia. Timely referrals to specialists avoid complications such as cardiac failure, liver cirrhosis, and endocrine disorders. Counselling for both patients and families to help patients and families cope with the upsets of living with a chronic illness- psychosocial attention- is also important.⁷

Breakthroughs and future perspectives

Significant advancements over the last decade in treating thalassaemia have transformed the trajectory for these children. However, advances in gene therapy, newer chelation drugs, and less morbid stem cell transplantation will hopefully lead to a day when thalassaemia becomes more manageable. Moreover, healthcare strategies such as enhancement of genetic counselling and prenatal screening will also be critical in dealing with the thalassaemia burden.^1,2,6

Summary 

Thalassaemia is a complex, chronic disorder with unique challenges in the paediatric population. Managing the condition and ensuring a better quality of life requires accurate early diagnosis, appropriate blood transfusions, iron chelation management, and new techniques like stem cell transplantation and gene-ridded therapy. 

However, a multidisciplinary approach, which encompasses medical, psychological, and social support, is critical to treating different aspects of the disease. As medical research and treatment continue to advance, the prognosis for children with thalassaemia continues to improve, giving hope to families affected by this disease.